2 finally, 1.0 µM imatinib for 2 months. The KCL-22R cell line resistant to 4 µM imatinib was established by gradually exposing KCL-22 cells to increasing concentrations of imatinib in the medium, beginning with 0.4 µM imatinib for 1.5 months, followed by 1.2 µM for 0.5 month, then, 4.0 µM. The presence of BCR-ABL1 kinase domain mutations in the established resistant cell lines was determined at the transcript level by next-generation deepsequencing (NGS) on a GS Junior platform (454 technology; Roche Applied Science, Basel, Switzerland) using BCR-ABL1 assays developed and distributed within the framework of the IRON-II phase study (Interlaboratory RObustness of NGS) 41 . A previously established protocol was used for NGS analysis 42 . No BCR-ABL1 mutant transcripts were detected in the K562R cell line, whereas the E255K mutation was present in 100 % of BCR-ABL1 transcripts from the KCL-22R cell line. The K562 and KCL-22 cells were verified by PCR detection of specific mRNA fusion variants of BCR-ABL1 gene (b3a2 for K562 and b2a2 for and KCL-22 cells were further verified by mBAND/mFISH analysis. No cell lines used in this work are listed in the database of commonly misidentified cell lines.
Transient transfection and cell treatment
Leukemic cells (10 6 ) were transfected with 30 nM synthetic hsa-miR-150 (ID: PM10070; Thermo Fisher Scientific, Waltham, MA, USA), 50 nM siRNA BCR-ABL1 (siRNA Duplex HPLC SR-HP001-001-29349990; Eurogentec, Seraing, Belgium), 50 nM siRNA MYB (Stealth siRNA MYBHSS106819, cat. #127985B05, Thermo Fisher Scientific) and 1 µg of a pMaxGFP expressing vector (Lonza Group AG). The BCR-ABL1 siRNA was designed as previously described 43 . All leukemic cell lines were cultured in triplicate. Cells were transfected via electroporation using a nucleofector device (Amaxa NucleofectorTM II, Lonza) and the appropriate nucleofection kits according to the manufacturer's instructions. K562 and KCL-22 cells were cultivated in the presence of 1 µM imatinib and in the presence 1 or 5 µM bromodomain inhibitor JQ1 (Sigma-Aldrich, St. Louis, MO, USA).
siRNA BCR-ABL1 design
Custom siRNA Duplexes-siRNA Duplex HPLC purified (10 nmol) were designed by a commercial supplier (Eurogentec). The design of siRNA Duplex was as follows: b3a2_1, 5-GCAGAGUUCAAAAGCCCUUdTdT-3 b3a2_3, 5-AGCAGAGUUCAAAAGCCCUdTdT-3 b3a2_1, 5-AAGGGCUUUUGAACUCUGCdTdT-3 b3a2_3, 5-AGGGCUUUUGAACUCUGCUdTdT-3
The stealth siRNA MYB design UAUAGUGUCUCUGAAUGGCUGCGGC RNA isolation and RT-qPCR 3 Total cellular RNA enriched for small RNAs was isolated from primary cells using the MirVana miRNA Isolation Kit according to the manufacturer's instructions (Thermo Fisher Scientific). Total cellular RNA was isolated from leukemic cell lines using the TRIzol Reagent (#15596026; Thermo Fisher Scientific) according to the standard operating procedure established in our laboratory. RNA quality and quantity were analyzed on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). To measure GUSB, BCR-ABL1, MYB, MYC and PU.1 expression levels, 200 ng of RNA was transcribed using 200 U/µl of M-MLV Reverse Transcriptase-l (#28025013; Thermo Fisher Scientific) using random hexamers. To measure RNU48, miR-150 and miR-155 levels, reverse transcription was performed using 50 U/µl MultiScribe Reverse Transcriptase (#4319983; Thermo Fisher Scientific) with RT-specific primers (5x). To measure the expression of pri-miR150, pre-miR150 and HPRT1, reverse transcription was performed using the iScript cDNA Synthesis Kit (#170-8891; BioRad Laboratories, Hercules, CA, USA). The conditions used for the reverse transcription reactions were set according manufacturer instructions. TaqMan Gene Expression Assays Hs00193527_m1 20x for MYB and Hs2786711_m1 20x Mix for PU.1 (SPI1) (Thermo Fisher Scientific) and the TaqMan MicroRNA Assays RT000473 20x for hsa-miR-150, RT002623 20x for hsa-miR-155 and RT001006 20x for the housekeeping gene RNU48 (Thermo Fisher Scientific) were used to perform relative quantification using TaqMan Universal Master Mix II (#4427788; Thermo Fisher Scientific) on the StepOnePlus system (Thermo Fisher Scientific). Transcript quantification of BCR-ABL1 is standardized in our laboratory using the European Treatment and Outcome Study (EUTOS) for CML project, and data are reported according to the International Scale (IS) 44, 45. Primers and probes for BCR-ABL1 and the housekeeping gene GUSB have been validated and applied according to Europe against Cancer recommendations 46 . Pri-and pre-miR-150 expression was quantified using specific primers (appropriate sequences were kindly provided by Prof. Jianjun Chen, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA) using SYBR Green-based PCR 22 ). RT-PCR conditions were set according manufacturer instructions as follows: 95°C for 10 min; and 45 cycles of 95°C for 15 sec and 60°C for 1 min. The converted CT values of specific (s) and control (c) amplicons calculated using the 2 -(CTs-CTc) equation were compared using Student's t-test.
Protein isolation and immunoblotting
The cells (10 6 ) were lysed for 15 min in RIPA buffer (50 mM Tris-Cl, pH 8.0, 137 mM NaCl, 1 % NP-40, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate, and protease inhibitor cocktail 1:1000 dilution P8340; Sigma-Aldrich) and sonicated using an M500 digital sonifier (Emerson, St. Louis, MO, USA). The denatured cell lysates (10 µg of protein per sample) were resolved on 4 %-12 % gradient Bis-Tris gels (NuPage; Thermo Fisher Scientific). The gels were dry-blotted on an iBlot Gel Transfer System according to the manufacturer's instructions (Thermo Fisher Scientific). The primary antibody (diluted 1:500) anti-v-MYB/c-MYB [EP769Y] (Abcam, Cambridge, UK) was used. Anti-β-Actin [AC-15] (Santa Cruz Biotechnology, Dallas, TX, USA) at 1:1000 or anti-β-actin horseradish peroxidase-conjugated (HRP) antibody [I-19] at 1:10000 (Santa Cruz Biotechnology) was used to determine sample loading. The secondary HRP-conjugated antibody anti-rabbit (#711-030-152; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was used at 1:3000 dilution. Bands were visualized using the ECL Plus Western Blotting Detection System (GE Healthcare, Chicago, IL, USA) on CL-4 XPosure films (Thermo Fisher Scientific). Bands were quantified using ImageJ (National Institute of Mental Health, Bethesda, MD, USA).
Chromatin immunoprecipitation
Formaldehyde cross-linked chromatin from 1x10 7 K562, KCL-22 and HL-60 cells and from separated CD34 + and CD34primary cells was prepared as previously described 47 using Anti-MYC (ab56 [9E11]; Abcam) or control IgG (NI01; Calbiochem®, Merck KGaA, Darmstadt, Germany). The enrichment quantification was performed as previously described 48 .
miRNA RNA sequencing
Total RNA (100 ng) from FACS-purified CD34 + CD38and CD34 + CD38 + cell fraction of nonidentifiable BM samples from healthy donors (n=3) and untreated CML patients in chronic (n=3) and blastic (n=3) phases was used in RNA sequencing for assessing differences in miR-150 and miR-155 expression. Sequences of miR-150 and miR-155 were applied from miRbase. miRNA libraries were prepared using a modified version of the TruSeq Small RNA Library preparation kit (Illumina, San Diego, CA, USA). According to the manufacturer's protocol, adapters were diluted 1:2 for sample input under 150 ng. Samples with input over 150 ng used 1X adapters. Post adapter annealing and cDNA synthesis samples were subject to 15 cycles of PCR per manufacturer's protocol. The 3' and 5' adapters were replaced by adaptors from TriLink Biotechnologies (San Diego, CA, USA). All other reagents and incubation times were as prescribed in the TruSeq protocol. The final library size selection was performed by gel selection on a 3 % agarose gel. Fragments between 140-160 bp were cut and extracted from the agarose using the Qiagen gel extraction kit (cat. number 28704, Qiagen, Valencia, CA, USA). Post purification samples were evaluated for size, quality, and quantity on the Perkin Elmer Gx. Using GX quantification, samples were pooled in equimolar amounts. The sample pool was further quantified using the Kapa Library Quantification Kit (cat. number KK4873). The sample pool was diluted to 2 nM, denatured with 0.1 N sodium hydroxide and loaded on a MiSeq sequencing system for 50 cycles of sequencing using a MiSeq ReagentKit v2 (catalog number MS-102-200). Final library QC was performed using the LabChip XT (Caliper Life Sciences, Hopkinton, MA, USA). Following standard data processing and demultiplexing, adaptor trimming was performed using Trimmomatic. The number of reads that overlapped with each miR-150 and miR-155 sequences from miRBase v21 after alignment with human genome GRCh38 was calculated using miRDeep quantifier module 49, 50 . We normalized the read counts for all samples to counts per million (CPM) by dividing the total read counts of a miRNA by the total read counts of the sample and multiplying this number by 10 6 . We used the normalized read counts per miRNA to look at the expression profile of the miRNAs.
Cell cycle and cell viability analyses
Cells (1-2 x 10 6 ) were washed with Annexin V binding buffer (#422201; BioLegend). The cell pellets were stained with 1 µM Annexin V -APC (#640920; BioLegend) for 15 min in the dark. Cells were fixed with 0.5 ml of 2 % formaldehyde (F8775; Sigma) for 10 min at room temperature and then permeabilized by incubation with 1 ml of 70 % ethanol for 30 min in 5 the dark. The cells were repeatedly washed with 1 % BSA in PBS and then stained with 1 µM FxCycle TM Violet Stain (F10347; Thermo Fisher Scientific). Cell cycle phases and cell viability were determined by FACS (BD FACS Canto II, Becton Dickenson).
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